Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
D000328:Adult; D006585:Altretamine / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D012306:Risk; D014227:Triazines / Q000008:administration & dosage*
D014227:Triazines; D004317:Doxorubicin; D003520:Cyclophosphamide; D006585:Altretamine